Skip to content

Corporate Sponsored Funding

PIVOT Center works with companies to thoroughly understand their R&D goals and match them to research goals of the appropriate faculty members at the University of Utah. PIVOT’s Corporate Engagement team works across all schools and units to facilitate partnerships and offer expertise on identifying opportunities that include grant funding, sponsored research and creating strategic corporate partnerships. PIVOT also provides guidance to faculty for successful stewardship. Please contact Sadhna Kohli (Director of Corporate Engagement) for more information regarding these opportunities, or if you have any questions.


Jump to:

Amazon Research: Alexa Fairness in AI

Oldcastle Infrastructure: Removing Nitrogen from Urban Stormwater Runoff

Pfizer: NSCLC Therapy Management for Optimal Outcomes

Pfizer: Topical Hemostasis in Minimally Invasive Surgery

Pfizer/Astellas/NCCN: Enzalutamide in the Treatment of Prostate Cancer

Pfizer: Pre-clinical & Translational Research in Multiple Myeloma

Chan Zuckerberg Initiative: Ancestry Networks for the Human Cell Atlas RFA

Pfizer: Addressing Primary Immunodeficiencies within Minority/Underserved Populations

Takeda: 2022 Innovators in Science Award in Gastroenterology

Pfizer: Pediatric Endocrinology Fellowship

Pfizer: 2021 Growth Hormone Research

Pfizer: Quality Improvement Grants to Support the Delivery of Gene Therapies to Patients with Rare Disease

Pfizer: Acromegaly

Pfizer: Transthyretin Cardiac Amyloidosis Fellowship

Pfizer: Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis Pain

Pfizer: Centers for Therapeutic Innovation (CTI)


Amazon Research: Alexa Fairness in AI
Amount:
Varies
Deadline: April 23, 2021

Alexa AI-Natural Understanding’s (NU) mission is to build and enable engaging, world-class conversational AI capabilities that are broadly accessible. Under this call for proposals, Amazon Research are seeking to fund research projects on the following topics:

  • Transparency, explainability, and accountability in AI systems
  • Theories of computational/algorithm fairness and factors that affect algorithmic trustworthiness
  • Detecting and ameliorating adverse biases in data and algorithms, and fairness-aware design of algorithms
  • Metrics and methods for designing, piloting, and evaluating systems that mitigate against adverse biases and ensure fairness, including the use of human-machine collaboration and decision support

Click here to learn more!


Oldcastle Infrastructure: Removing Nitrogen from Urban Stormwater Runoff
Amount: $40,000-75,000
Deadline: April 30, 2021

 Seeking technologies to remove nitrogen from urban stormwater runoff that can be used in combination with existing treatment methods, like bioretention, biofiltration or filtration.

Must-have requirements are:

  • Capable of reliably removing at least 50% of total nitrogen from urban stormwater
  • Can be deployed in urban stormwater drainage systems
  • Does not export pollutants, including sediment, phosphorus, or metals

Preferred requirements are:

  • A passive approach that does not require chemical or energy inputs
  • Accommodates treatment flow rates in the range of 1-2 gpm per square foot of treatment area
  • Capable of removing phosphorus as well as nitrogen

Click here to learn more!


Pfizer: NSCLC Therapy Management for Optimal Outcomes
Amount: $150,000
Deadline: May 5, 2021

  • Projects that will be considered for Pfizer support will focus on development of an algorithm or tool to guide the optimal treatment and support of patients with ALK or ROS1 re-arranged NSCLC.
  • The output of the project can be electronic (e.g. EMR-based or Application-based) or paper (e.g. published or freely available to download).
  • Therapy-management guidance is needed at all lines of treatment (e.g., first-line 1L, second-line 2L) and should include anticipated and pro-active management of side effects (neurocognitive, lipidemic etc.)
  • Support is available to institutions interested in developing a therapy management tool that can used at their own center and also be made widely available to others through publication and other dissemination strategies. It is not our intent to support clinical research projects.
  • Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Click here to learn more!


Pfizer: Topical Hemostasis in Minimally Invasive Surgery
Amount: $200,000
Deadline: May 12th, 2021

Projects that will be considered for Pfizer support will focus on educating surgeons and other healthcare professionals on topical hemostasis in minimally invasive surgical (MIS) procedures, addressing knowledge and practice gaps specific to perioperative bleeding during MIS including robotically-assisted procedures.  interested in programs that focus on some or all of the following: 

  • Management of capillary, venous and arteriolar bleeding in MIS
  • Preparation and use of topical hemostatic agents in MIS operating room environment
  • Delivery of topical hemostatic agents to difficult-to-access & difficult-to-visualize operative sites/sites of bleeding
  • Assessment of bleeding severity and effectiveness of topical hemostats in MIS

Click here to learn more!


Pfizer/Astellas/NCCN: Enzalutamide in the Treatment of Prostate Cancer
Amount:
Varies
Deadline: LOI due on May 14, 2021

The overall aim is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment of prostate cancer. Clinical trials, prospective studies, and retrospective correlative studies of enzalutamide treatment trials or datasets are encouraged. It is hoped proposals submitted in response to this RFP will guide development of enzalutamide and its combination with other therapies. Studies with correlative endpoints will be accepted, and studies that retrospectively analyze biomarkers (tissue, liquid biopsy, and other approaches) within prospective trials or datasets will be accepted.

Click here to learn more!


Pfizer: Pre-clinical & Translational Research in Multiple Myeloma
Amount: $150,000
Deadline: May 17, 2021

Only pre-clinical projects with a focus on these areas of interest will be considered for Pfizer support at this time:

  • Correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRDnegativity, and response to prior therapy
  • Understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS, OS)
  • Mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion)
  • Correlation between Soluble BCMA and BCMA expression on myeloma cells
  • Impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels
  • Mechanistic understanding of the impact of anti-myeloma agents (e.g., IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity
  • Exploring in-vitro or in-vivo novel combinations with elranatamab (PF06863135) Zuckerman Scholars enjoy unique programming and activities organized especially for them by their host universities and the Zuckerman Institute in Israel, including touring, educational experiences, and social programs. These activities are designed to strengthen the scholars’ knowledge of and connection to Israel, and cultivate an esprit de corps, exchange of ideas, and foster new relationships.

Click here to learn more!


Chan Zuckerberg Initiative: Ancestry Networks for the Human Cell Atlas RFA
Amount: Varies
Deadline: May 21, 2021

This Request for Applications (RFA) is intended to bring together teams of experts to 1) ethically and appropriately generate data derived from tissues from people whose ancestral groups are historically understudied and thereby expand the ancestral diversity of single-cell data that is available via the HCA, and 2) utilize best practices and build up systems to enable long-term engagement of potential participants and donors from diverse communities to contribute to the current and future drafts of the HCA. This work will help provide insights into the contribution of genetic ancestry to disease now and in the future, resulting in an atlas that may be more generalizable and representative of the diversity found in the global human population.

Click here to learn more!


Pfizer: Addressing Primary Immunodeficiencies within Minority/Underserved Populations
Amount: $200,000
Deadline: May 25, 2021

Primary immunodeficiencies occur in all patient populations but the

diagnoses are infrequently made in minority populations in the US. These

disparities have been noted in several studies. Through this RFP, the intent is to support patient and provider educational programs on the awareness, diagnosis, and treatment of primary immunodeficiencies within minority/underserved populations.

Click here to learn more!


Takeda: 2022 Innovators in Science Award in Gastroenterology
Amount: $200,000
Deadline: Nomination deadline May 27, 2021

Established in 2016, the Innovators in Science Award is administered by the New York Academy of Sciences and sponsored by Takeda Pharmaceuticals. This global award recognizes a promising Early-Career Scientist's and an outstanding Senior Scientist's contributions to biomedical science and is intended to support their commitment to innovative research.

Two prizes of US$200,000 are awarded each Award cycle to winning scientists who have distinguished themselves for the creativity and impact of their research in a designated therapeutic area.

Click here to learn more!


Pfizer: Pediatric Endocrinology Fellowship
Amount: $75,000
Deadline: June 1st, 2021

The intent is to support institutions with fellowship programs for Pediatric Endocrinologists that have a strong focus on clinical practice, research, and education to further the understanding of short stature/growth failure

Click here to learn more!


Pfizer: 2021 Growth Hormone Research
Amount: $100,000
Deadline: June 1st, 2021

Research projects that will be considered for Pfizer support will advance the medical knowledge of short stature.  Projects submitted may include:

  • Diagnostics, early treatment, new treatment paradigms
  • Clinical outcomes, quality of life, and patient reported outcomes
  • Medication adherence research
  • Translational or clinical research

Click here to learn more!


Pfizer: Quality Improvement Grants to Support the Delivery of Gene Therapies to Patients with Rare Disease
Amount: $50,000
Deadline: June 1, 2021

Projects that will be considered for Pfizer support will focus on preparing and/or optimizing multidisciplinary care teams for the integration of gene therapy into the treatment armamentarium for patients with a Rare Disease. Support is available for the development of leadership, best practices, SOP development, site readiness, support and/or training of HCPs within a multidisciplinary team environment to optimize the quality of care for patients who have/will have gene therapy in their treatment armamentarium.  

Projects that address recombinant adeno-associated virus gene therapy in Rare Disease and are therapeutic area and disease area agnostic (i.e., platform) will be prioritized. It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. 

Click here to learn more!


Pfizer: Acromegaly
Amount: $100,000
Deadline: June 1st, 2021

Projects that will be considered for Pfizer support will focus on:

  • Morbidity and mortality in Growth Hormone Excess
  • Novel strategies including Quality of Life and Patient Reported Outcomes to evaluate and treat Growth Hormone Excess
  • Early diagnosis and treatment of Growth Hormone Excess
  • Pathophysiology of Growth Hormone Excess 

Click here to learn more!


Pfizer: Transthyretin Cardiac Amyloidosis Fellowship
Amount: $80,000
Deadline: June 15th, 2021

The intent is to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis. Grants will be available for both established and emerging Amyloid Centers of Excellence.

Click here to learn more!


Pfizer: Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis Pain
Amount: $200,000
Deadline: June 18th, 2021

The intent is to support virtual and potentially live programs and other innovative digital medical education for Health Care Professionals. The focus is on Osteoarthritis and Chronic Pain associated with OA and patient-centered standard of care and management including pain and function, the biopsychosocial aspects of the disease, the complexities and challenges of care, and the future of OA/OA pain management. Programs targeted towards reviewing data at virtual or live osteoarthritis, rheumatology, pain, primary care, or other associated medical conferences, including but not limited to OARSI, EULAR, PAINWeek, AAFP, WCO, and ACR are of particular interest, as well as other meaningful education outside of congresses.

Click here to learn more!


Pfizer: Centers for Therapeutic Innovation (CTI)
Amount:
Varies
Deadline: June 28, 2021

Pfizer’s Centers for Therapeutic Innovation (CTI) Call for Proposals (CFP) to share details about our areas of interest and the timeline for submission of non-confidential pre-proposals this round. CTI focuses on accessing cutting-edge science and innovative discoveries aligned with Pfizer’s current core research areas of Oncology, Inflammation & Immunology, Rare Diseases, and Internal Medicine.

Click here to learn more!

Share this article:

 

Last Updated: 5/6/21